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At its Consensus Development Panel on Osteoporosis in
2001, the National Institutes of Health defined osteoporosis
as "a skeletal disorder characterized by compromised bone
strength predisposing a person to an increased risk of frac-
ture. Bone strength primarily reflects the integration of bone
density and bone quality"1. The issue of bone quality as a fac-
tor in osteoporotic fracture has received increasing attention
in recent years because the reduction in vertebral fracture
risk subsequent to treatment with anti-resorptive agents
appears to have little relationship to the percentage increase
in bone mineral density (BMD). Moreover, the increase in
fracture risk with age in untreated patients is only partly a
function of changes in BMD. The risk of fracture in a 75-
year-old woman is 4-7 times that of a 45-year-old woman
with an identical bone mass, demonstrating a bone quality
component to fragility that is independent of bone mass.
This shows that there is a component to bone fragility that is
independent of bone mass, and determined by bone quality.
Bone quality is defined by four characteristics of the bone
tissue matrix and skeletal physiology: (1) the rate of bone
turnover; (2) the properties of the collagen/mineral matrix;
(3) microdamage accumulation and (4) skeletal architecture
and geometry.
Rapid turnover accelerates osteoclastic resorption on tra-
becular surfaces that can reduce their resistance to buckling
and make failure more likely2. Ultimately, increased resorp-
tion will increase the probability for perforation and elimi-
nation of trabecular struts3,4. Reduced turnover by anti-
resorptive treatments may reduce fracture risk by more than
expected given the magnitude of BMD increases by prevent-
ing this weakening of trabecular struts and increasing tra-
becular thickness. A computational model developed by
Weinans5 shows that there is a nonlinear relationship
between the rate of bone turnover and the number of com-
plete trabecular perforations that will result over time.
Reducing the remodeling space by 50% (from 5.2% to 2.6%)
reduces the number of perforations by 75% over 200 remod-
eling cycles, suggesting that a suppression of bone turnover
may have a larger effect on bone strength than one would
expect from the amount of suppression alone.  
Using data from a one-year clinical trial with transdermal
estrogen administered by Lufkin et al.6, Riggs and Melton
show that vertebral fracture rate is determined by both BMD
and bone turnover rate7. This analysis shows that vertebral
fracture rate per 1,000 person years is increased at both low
BMD (< 0.8 g/cm2) and at a high bone formation rates
(>4.0%/yr) in placebo treated individuals. In those patients
in which remodeling was suppressed using transdermal
estrogen, vertebral fracture rate was determined only by low
BMD.
An increased rate of bone turnover does not always weak-
en bone. In some cases, increased turnover can also be asso-
ciated with increased strength and reduced fracture risk.
PTH increases bone turnover on trabecular surfaces and in
cortical bone near the endocortical surface, but the increase
in net bone formation and positive architectural changes cre-
ated by increased turnover are associated with increased
strength8,9. In cortical bone, the increased turnover occurs
close to the marrow cavity, and is more than offset by
increased periosteal apposition10, which maintains or
increases the cross-sectional moment of inertia.
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